Business Description
Paradigm Biopharmaceuticals Ltd
ISIN : AU000000PAR5
Description
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.56 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 1.56 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -2.42 | |||||
Beneish M-Score | -3.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 28.7 | |||||
3-Year EPS without NRI Growth Rate | 31.7 | |||||
3-Year FCF Growth Rate | 27.5 | |||||
3-Year Book Growth Rate | -32.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.7 | |||||
9-Day RSI | 49.26 | |||||
14-Day RSI | 49.13 | |||||
3-1 Month Momentum % | -28.33 | |||||
6-1 Month Momentum % | -44.42 | |||||
12-1 Month Momentum % | -40.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.31 | |||||
Quick Ratio | 1.31 | |||||
Cash Ratio | 0.88 | |||||
Days Sales Outstanding | 38583.54 | |||||
Days Payable | 188656.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.4 | |||||
Shareholder Yield % | -32.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 91.67 | |||||
Operating Margin % | -64870 | |||||
Net Margin % | -60151.67 | |||||
EBITDA Margin % | -57706.67 | |||||
FCF Margin % | -46122.5 | |||||
OCF Margin % | -45292.5 | |||||
ROE % | -176.81 | |||||
ROA % | -130.32 | |||||
ROIC % | -407.3 | |||||
3-Year ROIIC % | 3243.06 | |||||
ROC (Joel Greenblatt) % | -1440.4 | |||||
ROCE % | -167.81 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 12.86 | |||||
Price-to-Tangible-Book | 13.21 | |||||
EV-to-EBIT | -1.88 | |||||
EV-to-EBITDA | -1.89 | |||||
EV-to-Revenue | 1090.35 | |||||
EV-to-FCF | -2.34 | |||||
| Price-to-Net-Current-Asset-Value | 13.21 | |||||
Earnings Yield (Greenblatt) % | -53.19 | |||||
FCF Yield % | -39.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PBIGF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Paradigm Biopharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.04 | ||
| EPS (TTM) ($) | -0.065 | ||
| Beta | 0.0694 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.04 | ||
| Volatility % | 81.94 | ||
| 14-Day RSI | 49.13 | ||
| 14-Day ATR ($) | 0.016713 | ||
| 20-Day SMA ($) | 0.132285 | ||
| 12-1 Month Momentum % | -40.44 | ||
| 52-Week Range ($) | 0.10086 - 0.3468 | ||
| Shares Outstanding (Mil) | 584.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Paradigm Biopharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Paradigm Biopharmaceuticals Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-19 11:00 | In 142 days | ||
| First quarter earnings results for 2027 | 2026-10-29 | In 120 days | ||
| Annual report for 2026 | 2026-08-28 | In 58 days | ||
| Second quarter earnings results for 2026 | 2026-02-27 | 0.20 (+0.00%) | ||
| General meeting for 2025 | 2025-11-19 11:00 | 0.23 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-10-29 | 0.30 (-5.26%) | ||
| Annual report for 2025 | 2025-08-29 | 0.17 (-3.19%) | ||
| Third quarter earnings results for 2025 | 2025-04-29 | 0.13 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-02-27 | 0.38 (+0.00%) | ||
| General meeting for 2024 | 2024-11-19 11:00 | 0.14 (+0.00%) |
Show
Entries
Paradigm Biopharmaceuticals Ltd Frequently Asked Questions
What is Paradigm Biopharmaceuticals Ltd(PBIGF)'s stock price today?
The current price of PBIGF is $0.13. The 52 week high of PBIGF is $0.35 and 52 week low is $0.10.
When is next earnings date of Paradigm Biopharmaceuticals Ltd(PBIGF)?
The next earnings date of Paradigm Biopharmaceuticals Ltd(PBIGF) is 2026-10-29 Est..
Does Paradigm Biopharmaceuticals Ltd(PBIGF) pay dividends? If so, how much?
Paradigm Biopharmaceuticals Ltd(PBIGF) does not pay dividend.
Guru Commentaries on OTCPK:PBIGF
No articles.
Press Release
Articles on Paradigm Biopharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers